A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Population of Relapse or Refractory Chronic Lymphocytic Leukemia Patients in Routine Clinical Practice in Russian Federation (FORTE)

This study seeks to assess the effectiveness and safety of venetoclax in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) in a real-world setting across clinical practice in the Russian Federation.

Inclusion Criteria:

• Has a confirmed diagnosis of relapsed or refractory CLL.
• Patient for whom the physician has decided to initiate CLL treatment with venetoclax (mono and combo therapy), or up to 4 weeks after venetoclax treatment initiation
• Patient voluntarily agrees to participate in this study and signs informed consent form

Exclusion Criteria:

• Has contraindications to venetoclax as listed on the approved local label in Russian Federation.
• Has Richter syndrome
• Participated in a clinical trial with an investigative drug for CLL within 30 days prior to treatment initiation